Home > Keywords > Thématique > Partenariat

Partenariat

Articles

  • Vect-Horus Enters Exclusive License Agreement with Novo Nordisk to Develop Targeted Therapeutics
    1 November 2023, by Emmanuelle BETTENDORF

    Vect-Horus, a privately held biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced it has entered into a global license agreement with Novo Nordisk A/S. This agreement provides Novo Nordisk with worldwide, exclusive license to use Vect-Horus platform technology ”VECTrans”; for delivery of cargos directed against specified targets . Novo Nordisk has an option to add additional targets to the (…)

  • Vect-Horus Enters Exclusive License Agreement with Ionis Pharmaceuticals to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases
    30 January 2024, by Emmanuelle BETTENDORF

    Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced it has entered into a global license agreement with Ionis Pharmaceuticals, Inc. (Nasdaq: IONS). The agreement provides Ionis with a worldwide, exclusive license for a specified number of targets using Vect-Horus’ platform technology ”VECTrans” for systemic delivery of RNA-targeted therapeutics that (…)

  • Vect-Horus announces collaboration and license option agreement with Servier to develop targeted oligonucleotide therapeutics for rare CNS diseases
    30 June, by Emmanuelle BETTENDORF

    Vect-Horus is pleased to announce that we have entered into a research evaluation and exclusive license option agreement with Servier, an independent international pharmaceutical group, to develop targeted oligonucleotide therapeutics for the treatment of central nervous system (CNS) diseases.
    Under the agreement, we will leverage our proprietary VECTrans® technology platform to facilitate the transport of Servier’s oligonucleotide therapeutics across biological barriers to the brain, (…)

  • Vect-Horus Enters a CNS-Focused Research Collaboration with OliX Pharmaceuticals
    3 February, by Emmanuelle BETTENDORF

    We are delighted to announce we have entered into a Material Transfer and Evaluation Agreement with OliX Pharmaceuticals, a leading developer of RNAi therapeutics, to initiate a collaboration focused on siRNA delivery for central nervous system (CNS) disorders.
    “We are extremely pleased to partner with OliX. This collaboration underscores Vect-Horus’ leadership in BBB technology and its commitment to advancing oligonucleotide therapeutics in CNS diseases through strategic partnerships with (…)

  • Vect-Horus announces agreement with Johnson&Johnson Innovation
    18 January 2019, by Jonathan NOWAK

    Vect-Horus announced today the signing of a research collaboration agreement with Janssen Pharmaceuticals, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

  • Vect-Horus enters into Collaboration and License Agreement with ONO Pharmaceutical Co., Ltd.
    26 March 2019, by Jonathan NOWAK

    Vect-Horus S.A.S. announced today the signing of a collaboration and license agreement with Ono Pharmaceutical Co., Ltd., focused on the development of novel molecules targeting neurodegenerative diseases

  • Vect-Horus further strengthens leadership with appointment of strategy and finance executive Jérôme Berger to its Board of Directors
    3 February 2025, by Emmanuelle BETTENDORF

    We are excited that Jerome Berger is joining our Board of Directors!
    Jerome brings vast expertise in strategy, finance, and venture capital in the technology and life sciences sectors, which will be invaluable as Vect-Horus accelerates its growth and development.
    “Jerome’s unparalleled experience in strategy, venture capital and global financing, coupled with his strong background in digital health and life sciences, will be invaluable in supporting the development of Vect-Horus as we (…)

  • Secarna Pharmaceuticals and Vect-Horus Announce Research Collaboration to Advance Systemic Delivery of RNA-Targeted Therapeutics for CNS Disorders
    11 July 2025, by Emmanuelle BETTENDORF

    We are proud and excited to announce a new strategic research collaboration with Secarna Pharmaceuticals!
    The partnership will focus on developing RNA-targeted therapeutics capable of crossing the blood-brain barrier (BBB) to address diseases of the central nervous system (CNS), combining our delivery technology platform, VECTrans®, with Secarna’s proprietary OligoCreator® oligonucleotide discovery platform.
    The combination of these two technologies will expand Secarna’s targeted (…)

  • Relocation of the company to support its development
    1 October 2019, by Elodie DORMES

    Relocation of Vect-Horus in medical faculty of the La Timone campus to maintain strong collaborative working environment with its historical partners and support its development.

  • Vect-Horus and RadioMedix announce the signing of a LOI to co-develop a Vect-Horus’ radio-theranostic agent for Glioblastoma
    6 March 2019, by Jonathan NOWAK

    Marseille, France- Houston - March 5, 2019 - Vect-Horus and RadioMedix announced today the signing of a Letter of Intent (LOI) to establish an agreement for the co-development of a Vect-Horus theranostic agent for the diagnostic and radiotherapy of Glioblastoma Multiforme (GBM) of the brain.
    This partnership will marry the expertise of Vect-Horus in targeting tumors with its technology VECTrans® and the know-how of RadioMedix in developing and conducting pre-clinical evaluation and (…)